Dr. Parul Thakral - Ph.D, M.Sc., Clinical Research Officer | Nuclear Medicine Expert in India

Dr. Parul Thakral

With a Ph.D in Radiochemistry & Clinical Nuclear Medicine from one of Asia’s Premier Institutes, AIIMS (All India Institute of Medical Sciences), Dr. Parul Thakral is currently working as a Clinical Research Officer in the Department of Nuclear Medicine & Molecular Imaging at Fortis Memorial Research Institute (FMRI), Gurgaon.

Dr. Parul’s interest in Clinical Research began during her school days. After completing her graduation, B.Sc – Medical Technology in Radiography, and post-graduation, M.Sc. – Nuclear Medicine Technology from AIIMS, she started working as a Senior Research Fellow on a DST Funded Projects at the Department of Nuclear Medicine at AIIMS.

Dr. Parul’s Ph.D Thesis’ topic was “ASSESMENT OF THERAPEUTIC RESPONSE TO 90YTTRIUM (90Y) RADIOLABELLED CHIMERIC ANTI-CD20 ANTIBODY - RITUXIMAB IN PATIENTS OF RELAPSED/ REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA,” where she was involved conjugation & standardisation of Radiolabelling and quality control of Ant-CD20 Monoclonal Antibody Rituximab with 90-Yttrium, 68-Gallium & 177-Lutetium.

With Radiolabelling of Monoclonal Antibodies (Human & Non-Human) as her forte, Dr. Parul has extensive experience working with several Radionuclides & Radiopharmaceuticals, such as Tc-99m (TRODAT, Methionine) I-131, F-18(NaF, FDOPA, FLT), Ga-68 (DOTANOC, PSMA, Bisphosphonate), Lu-177 (Rituximab, DOTATATE, PSMA), Y-90 (Rituximab), Sr-89, Sm-155, P-32, Re-186 & Re-188. Apart from this, she also has expertise in Chromatographic Procedures (TLC & HPLC).

Dr. Parul is also an AERB Radiation Safety Officer (RSO), Level-II and a visiting faculty for M.Sc (Nuclear Medicine) at Ganesh Educational & Research Institute in New Delhi.


  • 2010-2011: Junior Research Fellow, Department of Nuclear Medicine, AIIMS, New Delhi.
  • 2011-2016: Senior Research Fellow, Department of Nuclear Medicine, AIIMS, New Delhi.
  • Assessment of Therapeutic Response to Yttrium-90 Radiolabelled Chimeric Anti-CD20 Antibody – Rituximab in patients of Relapsed and Refractory B-Cell Non-Hodgkin’s Lymphoma.
  • Study of Changes in Sleep Architecture, Melatonin Levels & Metabolic Abnormalities on F-18 Flurodeoxyglucose Positron Emission Tomography (FDG-PET) in person with Mild Cognitive Impairment (MCI) progressing to Alzheimer's Type Dementia (AD).


  • First prize in the 3rd International Medical Olympiad for Contribution in Radioimmunotherapy in Oncology.

Second Opinion

Start typing and press Enter to search